Core Viewpoint - The company reported a slight increase in revenue and net profit for 2024, but the performance was slightly below market expectations [2] Group 1: Financial Performance - The company achieved a revenue of 4.159 billion yuan in 2024, representing a year-on-year increase of 3.99% [2] - The net profit attributable to shareholders was 712 million yuan, up 15.04% year-on-year [2] - The non-recurring net profit was 647 million yuan, reflecting a year-on-year growth of 21.38% [2] - The operating cash flow was 726 million yuan, down 8.41% year-on-year [2] - The basic earnings per share (EPS) was 0.83 yuan [2] Group 2: Business Segments - The finished drug segment continued to grow, with revenue reaching 2.522 billion yuan, an increase of 8.42% year-on-year [3] - The innovative drug, Didasyn, was successfully included in the medical insurance directory, supporting future sales [3] - The raw material drug segment saw a revenue decline to 876 million yuan, down 8.37% year-on-year, primarily due to market fluctuations [4] - The medical device segment achieved revenue of 687 million yuan, growing by 7.84% year-on-year, despite challenges in the global market [4]